Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab

Xuehua Ke(Wilmington University), Jonathan Corren(California Allergy and Asthma Medical Group), Vincent J. Willey(Wilmington University), Judith J. Stephenson(Wilmington University), Benjamin Ortiz(Harlem Hospital Center), Reynold A. Panettieri(Rutgers, The State University of New Jersey), Liya Wang(Jiangsu University), Qing Huang(Wilmington University), Abhishek Kavati(Pfizer (United States)), Debra Wertz(Wilmington University)
Clinical Therapeutics
July 1, 2018
10.1016/j.clinthera.2018.05.014
Cited by 13

Related Papers

Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
|Allergy|2020|406
Incidence and Characteristics of Angioedema Associated With Enalapril
|Archives of Internal Medicine|2005|293
EAACI Biologicals Guidelines—Recommendations for severe asthma
|Allergy|2020|275
Safety and tolerability of omalizumab
|Clinical & Experimental Allergy|2009|253